COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 4 of 103 for:    "Alkermes, Inc." [Exact]

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03919994
Recruitment Status : Recruiting
First Posted : April 18, 2019
Last Update Posted : September 22, 2020
Information provided by (Responsible Party):
Alkermes, Inc.

Brief Summary:
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY MAINTENA®, ARISTADA®, INVEGA SUSTENNA® or RISPERDAL CONSTA®)

Condition or disease

Detailed Description:
This is a non-interventional, prospective, multi-center observational cohort study. Patients at behavioral health clinics will be enrolled and evaluated by health care professionals (e.g., psychiatrists) according to the standard of care. All patients will be followed for approximately 12 months from their enrollment visit.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: OASIS: Observational Study of LAIs In Schizophrenia
Actual Study Start Date : March 28, 2019
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia

Subjects newly initiated
Subjects newly initiated
Subjects newly initiated
Subjects newly initiated

Primary Outcome Measures :
  1. Schizophrenia disease history [ Time Frame: Baseline ]
    Including time (years) since diagnosis as assessed from clinical history

  2. Number of comorbid conditions at baseline [ Time Frame: Baseline ]
    Assessed from clinical history

  3. Changes in comorbid conditions [ Time Frame: Up to 12 months ]
    The percent of patients experiencing each comorbid condition will be assessed at follow-up visits

  4. Number of LAI injections [ Time Frame: Up to 12 months ]
    Average number of injections during treatment period

  5. Number of patients switching or discontinuing LAI treatment [ Time Frame: Up to 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with schizophrenia who are newly initiating LAI treatment

Inclusion Criteria:

  • Must be able to speak, read and understand English
  • Diagnosis of schizophrenia as defined by the treating clinician
  • Newly initiating treatment with 1 of 4 atypical Long Acting Injectables (LAIs): Abilify Maintena, Aristada, Invega Sustenna, or Risperdal Consta)
  • Additional criteria may apply

Exclusion Criteria:

  • Currently participating or planning to participate in an interventional clinical study, or has completed participation in an interventional clinical study within 30 days before enrollment
  • In the opinion of the investigator, is currently an imminent danger to himself/herself. [Note: A prior history of suicidal ideation or suicidal attempt is not exclusionary.]
  • Additional criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03919994

Layout table for location contacts
Contact: Worldwide Project Manager 984-208-9828

Show Show 53 study locations
Sponsors and Collaborators
Alkermes, Inc.
Layout table for investigator information
Study Director: Alkermes Medical Director Alkermes, Inc.
Layout table for additonal information
Responsible Party: Alkermes, Inc. Identifier: NCT03919994    
Other Study ID Numbers: ALKS 9072-A403N
First Posted: April 18, 2019    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Alkermes, Inc.:
Abilify Maintena
Invega Sustenna
Risperdal Consta
Cohort Study
Phase 4
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders